MedTrace Logo

A Safety and Pharmacokinetics Study of ZB004 in Healthy Participants

NCT05794516 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-04-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and pharmacokinetics of single-ascending doses of ZB004.

Conditions

  • Healthy Volunteers

Interventions

DRUG

ZB004

ZB004 single doses administered subcutaneously as solution

DRUG

Placebo

Placebo single doses administered subcutaneously as solution

Sponsors & Collaborators

  • Zenas BioPharma (USA), LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-06-19
Primary Completion
2024-03-21
Completion
2024-03-21

Countries

  • New Zealand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05794516 on ClinicalTrials.gov